Crossmark

Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial

Crossref DOI link: https://doi.org/10.1186/s13287-025-04130-x

Published Online: 2025-01-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nandula, Seshagiri Rao

Jain, Arad

Sen, Sabyasachi https://orcid.org/0000-0002-3675-9129
Funding

Funding for this research was provided by:

AstraZeneca United States (AstraZeneca United States)
License Information

Text and Data Mining valid from 2025-01-26

Version of Record valid from 2025-01-26
More Information

Article History

Received: 16 July 2024

Accepted: 5 January 2025

First Online: 26 January 2025

Declarations

:

: The authors declare that they have no competing interests. SS is one of the associate editors of the journal. All authors read and approved the final manuscript. The authors declare that they have not used Artificial Intelligence in this study.

: The study was approved by IRB board of GW university. Title Approved: Cardio-Protective Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients with Type 2 Diabetes. IRB Number: 180295. Initial Approval: 20th Sept 2018.

: Astra-Zeneca Investigator Initiated Funds given to Dr Sen.

Document is current

Any future updates will be listed below